Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-eb144117bf1832a81a0b81022c43f19d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-eb144117bf1832a81a0b81022c43f19d"/>
<resource>
<Composition>
<id value="composition-en-eb144117bf1832a81a0b81022c43f19d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-eb144117bf1832a81a0b81022c43f19d"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-eb144117bf1832a81a0b81022c43f19d</b></p><a name="composition-en-eb144117bf1832a81a0b81022c43f19d"> </a><a name="hccomposition-en-eb144117bf1832a81a0b81022c43f19d"> </a><a name="composition-en-eb144117bf1832a81a0b81022c43f19d-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/896/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - granupas</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/896/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpeb144117bf1832a81a0b81022c43f19d"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - granupas"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What GRANUPAS is and what it is used for</li><li>What you need to know before you take GRANUPAS</li><li>How to take GRANUPAS</li><li>Possible side effects</li><li>How to store GRANUPAS</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What granupas is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What granupas is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>GRANUPAS contains para-aminosalicylic acid which is used in adults and children aged 28 days and older to treat resistant tuberculosis in combination with other medicines, in cases of resistance or intolerability with other treatments.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take granupas"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take granupas"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take GRANUPAS</p><ul><li>if you are allergic to para-aminosalicylic acid or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have severe kidney disease. If you are not sure, talk to your doctor or pharmacist before taking GRANUPAS.</li></ul><p>Warnings and precautions Talk to your doctor or pharmacist before taking GRANUPAS</p><ul><li>if you have liver problems or mild or moderate kidney disease</li><li>if you have a stomach ulcer</li><li>if you are infected with HIV</li></ul><p>Children<br/>Use of GRANUPAS is not recommended in newborn babies (under 28 days of age).</p><p>Other medicines and GRANUPAS Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>It is especially important to tell your doctor if you are taking any of the following:</p><ul><li>Antituberculosis medicines or ethionamide (other treatments against tuberculosis)</li><li>Vitamin B* Digoxin (for heart disease)</li><li>Diphenylhydramine (for allergic reactions)</li><li>Tenofovir (for HIV/ hepatitis B infections)</li></ul><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. GRANUPAS is not recommended during pregnancy and should only be used if advised by your physician. Do not breastfeed whilst taking GRANUPAS. This is because small amounts of the medicine can pass into mother s milk.</p><p>Driving and using machines GRANUPAS is unlikely to affect your ability to drive any vehicle and use machines. In case it does, please report it to your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="3. How to take granupas"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take granupas"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Adults The recommended dose for adults is 1 sachet three times a day, with a schedule of 1 sachet every 8 hours. Your physician may need to start with a lower dose to prevent possible side effects. Do not take more than 3 sachets per day. Treatment is usually given for two years (24 months).</p><ul><li>Add the contents of the sachet to a drink of tomato or orange juice.</li><li>Drink straight away</li><li>If some granules are left in the glass, add some more juice and drink straight away.</li></ul><p>Use in infants, children and adolescents The dose in infants, children and adolescents will be calculated by your doctor based on the patient s body weight. The recommended total dose per day is 150 mg for each kg of body weight. This daily amount is divided into two doses spread out through the day.</p><ul><li>Use the spoon that comes with the medicine to measure the dose.</li><li>To measure the dose: * Lines on the spoon indicate the amount (in milligrams of para-aminosalicylic acid). Take the correct amount as prescribed by your doctor. * Put granules directly into the spoon. * Tap the spoon once on a table to give a horizontal level of granules and continue filling if necessary.</li><li>Sprinkle the granules onto apple sauce or yogurt.</li><li>Make your child eat it straight away.</li></ul><p>Taking this medicine</p><ul><li>Do not crush or chew the granules. Swallow the granules whole. It is important that you do not dissolve, crush or chew the granules as they may not absorb properly and may cause stomach ache or bleeding.</li><li>Do not use the sachet if it is swollen or the granules have lost their light brown colour.</li><li>You may notice granules appearing in your stools; this is normal.</li></ul><p>If you take more GRANUPAS than you should Speak to a doctor or pharmacist.</p><p>If you forget to take a dose of GRANUPAS Do not take a double dose to make up for a forgotten dose. Wait until the next dose is due, then take your normal dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>During the first 3 months of your treatment with GRANUPAS, you must be attentive to any sign of allergic reaction (for example skin eruption, itchy red spots on the skin, itching, rash, watery or itchy eyes or stuffy nose) or hepatitis (for example fever, fatigue, dark urine, pale stool, abdominal pain, yellow skin and eyes). If you experience any of these symptoms, you must contact to your doctor immediately.</p><p>Common side effects (may affect more than 1 in 100 people):</p><ul><li>giddiness,</li><li>stomach ache (abdominal pain),</li><li>vomiting,</li><li>nausea,</li><li>bloating,</li><li>diarrhoea,</li><li>soft stools,</li><li>skin redness or rash,</li><li>disturbance of gait and equilibrium.</li></ul><p>Uncommon side effects (may affect more than 1 in 1,000 people):</p><ul><li>loss of appetite (anorexia).</li></ul><p>Rare side effects (may affect more than 1 in 10,000 people):</p><ul><li>thyroid gland problems*,</li><li>reduced ability to absorb nutrients from food ulcer,</li><li>bleeding in the gut,</li><li>yellowing of skin or eyes (jaundice),</li><li>metallic taste,</li><li>itchy rash.</li></ul><p>(*) in subjects also infected with HIV thyroid gland problems and specifically underactive thyroid or low levels of thyroid hormones, are a very common side effect that may affect more than 1 in people. Regular monitoring of the thyroid function is indicated for all people living with HIV.</p><p>Very rare side effects (may affect less than 1 in 10,000 people):</p><ul><li><p>reduction in blood platelets,</p></li><li><p>red spots on the skin,</p></li><li><p>reduction in numbers of white blood cells,</p></li><li><p>reduction in numbers of red blood cells,</p></li><li><p>reduction of the ability of red blood cells to release oxygen</p></li><li><p>low levels of blood sugar,</p></li><li><p>tendon pain,</p></li><li><p>headache,</p></li><li><p>visual abnormalities,</p></li><li><p>nerve damage in the hands and feet,</p></li><li><p>dizziness,</p></li><li><p>crystals in urine.</p></li><li><p>prolonged bleeding time,</p></li><li><p>destruction of liver cells</p></li><li><p>elevated liver enzymes,</p></li><li><p>weight loss.</p></li></ul><p>Not known side effects (frequency cannot be estimated from the available data):</p><ul><li>Hepatitis.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store granupas"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store granupas"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and sachet after EXP. The expiry date refers to the last day of the month.</p><p>Do not store above 25 C. The sachets can be stored below 25 C up to 24 hours after opening.</p><p>Do not use this medicine if you notice the sachets are swollen or if the granules are dark brown or purple.</p><p>Do not throw away any medicines via wastewater or household waste.<br/>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What GRANUPAS contains<br/>The active substance is para-aminosalicylic acid. Each sachet of gastro-resistant granules contains 4 g of para-aminosalicylic acid. The other ingredients are silica, colloidal hydrated, dibutyl sebacate, methacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 per cent, hypromellose, cellulose, microcrystalline, talc.</p><p>What GRANUPAS looks like and contents of the pack This medicine is presented as light brown gastro-resistant granules in sachets.<br/>Each box contains 30 sachets. A calibrated measuring spoon is provided.</p><p>Marketing Authorisation Holder Eurocept International BV Trapgans 5 1244 RL Ankeveen The Netherlands</p><p>Manufacturer</p><p>Eurocept International BV Trapgans 5</p><p>1244 RL Ankeveen The Netherlands</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Lucane Pharma T l/Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Lietuva<br/>Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></p><p>Lucane Pharma Te .: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Luxembourg/Luxemburg Lucane Pharma T l/Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> esk republika Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Magyarorsz g Lucane Pharma Tel.: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Danmark Lucane Pharma Tlf: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Malta Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Deutschland Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Nederland Eurocept International BV Tel: +31 35 528 39 <a href="mailto:info@euroceptpharma.com">info@euroceptpharma.com</a> Eesti Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Norge Lucane Pharma Tlf: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></p><p>Lucane Pharma : + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> sterreich Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Espa a Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></p><p>Polska Lucane Pharma Tel.: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> France Lucane Pharma T l: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Portugal Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Hrvatska Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Rom nia Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></p><p>Ireland Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Slovenija Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> sland Lucane Pharma S mi: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Slovensk republika<br/>Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Italia Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Suomi/Finland Lucane Pharma Puh/Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></p><p>Lucane Pharma : + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Sverige Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> Latvija Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a> United Kingdom Lucane Pharma Tel: + 33 153 868 <a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></p><p>This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpeb144117bf1832a81a0b81022c43f19d"/>
<resource>
<MedicinalProductDefinition>
<id value="mpeb144117bf1832a81a0b81022c43f19d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpeb144117bf1832a81a0b81022c43f19d"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpeb144117bf1832a81a0b81022c43f19d</b></p><a name="mpeb144117bf1832a81a0b81022c43f19d"> </a><a name="hcmpeb144117bf1832a81a0b81022c43f19d"> </a><a name="mpeb144117bf1832a81a0b81022c43f19d-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/896/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: GRANUPAS 4 g gastro-resistant granules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/896/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="GRANUPAS 4 g gastro-resistant granules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
